These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 28110898)

  • 1. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
    Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
    Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
    Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
    PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
    Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
    Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
    Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?
    Tabata R; Kimura T; Kuruma H; Sasaki H; Kido M; Miki K; Takahashi H; Aoki M; Egawa S
    Cancer Med; 2016 Sep; 5(9):2314-22. PubMed ID: 27456710
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Smile TD; Tom MC; Halima A; Ciezki JP; Reddy CA; Stephans KL; Mian OY; Zhang RX; Klein EA; Campbell S; Ulchaker J; Angermeier K K; Tendulkar RD
    Brachytherapy; 2022; 21(1):85-93. PubMed ID: 34656435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
    Bittner N; Merrick GS; Wallner KE; Butler WM; Galbreath R; Adamovich E
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1078-84. PubMed ID: 19553031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
    Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
    Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
    Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
    Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
    Pickles T; Morris WJ; Keyes M
    Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.
    Andruska N; Michalski JM; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Fischer-Valuck BW; Baumann BC
    Brachytherapy; 2022; 21(3):317-324. PubMed ID: 35123889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Hamstra DA
    Am J Clin Oncol; 2016 Apr; 39(2):181-8. PubMed ID: 24517957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis.
    Oh J; Morris WJ; Spadinger I; Tyldesley S; Keyes M; Halperin R; Crook J; Lapointe V; Pickles T
    Brachytherapy; 2022; 21(5):605-616. PubMed ID: 35729030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.
    King MT; Chen MH; Moran BJ; Braccioforte MH; Buzurovic I; Muralidhar V; Yang DD; Mouw KW; Devlin PM; D'Amico AV; Nguyen PL; Orio PF
    Urol Oncol; 2018 Apr; 36(4):157.e15-157.e20. PubMed ID: 29276060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone.
    Andruska N; Fischer-Valuck BW; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Michalski JM; Baumann BC
    J Natl Compr Canc Netw; 2022 Feb; 20(4):343-350.e4. PubMed ID: 35193114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer.
    Slevin F; Zattoni F; Checcucci E; Cumberbatch MGK; Nacchia A; Cornford P; Briers E; De Meerleer G; De Santis M; Eberli D; Gandaglia G; Gillessen S; Grivas N; Liew M; Linares Espinós EE; Oldenburg J; Oprea-Lager DE; Ploussard G; Rouvière O; Schoots IG; Smith EJ; Stranne J; Tilki D; Smith CT; Van Den Bergh RCN; Van Oort IM; Wiegel T; Yuan CY; Van den Broeck T; Henry AM
    Eur Urol Oncol; 2024 Aug; 7(4):677-696. PubMed ID: 38151440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
    Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
    Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.